Gilead taps Nurix protein degrader option for $20M
Four years after first entering a collaboration with Nurix, Gilead is ponying up an option exercise payment of $20 million to license targeted protein degrader GS-6791.
It’s the first candidate to come from the agreement, with the potential for $425 million in milestone payments and low double-digit tiered royalties on product net sales.
GS-6791 is an oral IRAK4 degrader that targets inflammatory responses. Degrading IRAK4 could lead to potential treatments in rheumatoid arthritis and other inflammatory diseases, according to a press release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.